



Certificate of Analysis

www.tocris.com

Product Name: Dynorphin B Catalog No.: 3196 Batch No.: 3

CAS Number: 83335-41-5

1. PHYSICAL AND CHEMICAL PROPERTIES

Batch Molecular Formula: $C_{74}H_{115}N_{21}O_{17}$

Batch Molecular Weight: 1570.85

Physical Appearance: White lyophilised solid

Net Peptide Content: 70% Counter Ion: TFA

Solubility: Soluble to 0.60 mg/ml in water

Storage: Store at -20°C

Peptide Sequence: Tyr-Gly-Gly-Phe-Leu-Arg-Arg-Gln-Phe-Lys-Val-

Val-Thr

2. ANALYTICAL DATA

HPLC: Shows 96% purity

Mass Spectrum: Consistent with structure

3. AMINO ACID ANALYSIS DATA

Amino Acid Theoretical Actual Amino Ac				Acid Theoreti	cal Actual
Ala			Lys	1.00	1.03
Arg	2.00	1.97	Met		
Asx			Phe	2.00	1.97
Cys			Pro		
Glx	1.00	1.08	Ser		
Gly	2.00	2.00	Thr	1.00	0.86
His			Trp		
lle			Tyr	1.00	0.95
Leu	1.00	0.82	Val	2.00	1.77

Caution - Not Fully Tested • Research Use Only • Not For Human or Veterinary Use



Product Information

Print Date: Nov 3rd 2021

www.tocris.com

Product Name: Dynorphin B Catalog No.: 3196 Batch No.: 3

CAS Number: 83335-41-5

Description:

Dynorphin B is an opioid peptide that is the preferred endogenous agonist for the kappa opioid receptor. Displays moderate selectivity for κ_{1b} .

Physical and Chemical Properties:

Batch Molecular Formula: $C_{74}H_{115}N_{21}O_{17}$ Batch Molecular Weight: 1570.85

Physical Appearance: White lyophilised solid

Peptide Sequence:

Tyr-Gly-Gly-Phe-Leu-Arg-Arg-Gln-Phe-Lys-Val-Val-Thr

Storage: Store at -20°C

Solubility & Usage Info:

Soluble to 0.60 mg/ml in water

This product is supplied as a lyophilized solid and may be very hard to visualize. Solutions should be made by adding solvent directly to the vial. The vial should then be vortexed vigorously to ensure the product has completely dissolved.

Net Peptide Content: 70% (Remaining weight made up of counterions and residual water).

Counter Ion: TFA

Stability and Solubility Advice:

Some solutions can be difficult to obtain and can be encouraged by rapid stirring, sonication or gentle warming (in a 45-60°C water bath).

Peptides in solution are much less stable than in lyophilized form. This is especially true for peptides whose sequences contain amino acids such Cys, Met,Trp, Asn, Gln, and N-terminal Glu.

Therefore we recommend storing peptides in solution for as short a time as possible. Avoid repeated freeze thaw cycles by dividing the peptide solution into aliquots and storing the aliquots at -20°C. Any portion of an aliquot unused after thawing should be discarded.

Peptides stored in solution can occasionally be susceptible to bacterial degradation. We recommend using sterile solutions or passing the peptide solution through a 0.2 μ m filter to remove potential bacterial contamination whenever possible.

References:

Tan-No *et al* (2008) Cysteine protease inhibitors suppress the development of tolerance to mor. antinociception. Neuropeptides *42* 239. PMID: 18440066.

Pasternak et al (1999) Antisense mapping KOR-1: evidence for multiple kappa analgesic mechanisms. Brain Res. 826 289. PMID: 10224306.

Dhawan et al (1996) International union of pharmacology. XII. Classification of opioid receptors. Pharmacol.Rev. 48 567. PMID: 8981566.

Caution - Not Fully Tested • Research Use Only • Not For Human or Veterinary Use